About us


Visible science

Maintain vision and improve ocular health

Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.

The lead program of Nicox’s ophthalmic pipeline, NCX 470, is in Phase 3 clinical development targeting glaucoma. Our ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728, and a clinical-stage product candidate for dry eye disease licensed exclusively to a partner for the Chinese market, NCX 4251. We have two products which are commercialized in the U.S.; VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis, respectively, and which are being rolled-out in territories outside of the U.S. through partnerships.

We are focused on the discovery, development of novel ophthalmic therapeutics for eye diseases.

Disease focus areas

Leadership team

Nicox has a highly experienced leadership team. Their combined expertise, from leading pharmaceutical and biotech companies, covers research, clinical development, regulatory, finance, business and corporate development, alliance management and communication.

Nicox’s Board has extensive experience in ophthalmology and pharmaceutical development
World-recognized leading experts in ophthalmology

Ophthalmic partnerships



Nicox has entered an exclusive license agreement with ITROM Pharmaceutical Group to develop and commercialize ZERVIATE®  in the Gulf and Arab markets.

ITROM is a Dubai based pharmaceutical organization with over 20 years’ experience in the regional ophthalmological scene. The group maintains a unique focus on introducing breakthrough and innovative pharmaceutical products within the MENA region, with Ophthalmology and Women’s Health specialties placed at the forefront of its development activities.


Nicox and Ocumension Therapeutics entered into exclusive license agreements for the development and commercialization of  ZERVIATE® and NCX 470 for the Chinese and Southeast Asian markets as well as for NCX 4251 for the Chinese market.

Ocumension Therapeutics is a China-based ophthalmology company, listed on Hong Kong Exchange, dedicated to identifying, developing and commercializing first or best-in-class ophthalmic therapies.


Nicox entered into an exclusive worldwide licensing agreement with Bausch + Lomb which grants Bausch + Lomb exclusive worldwide rights to develop and market latanoprostene bunod, commercialized as VYZULTA®.

Bausch + Lomb, a leading global eye health company, is dedicated to helping people see better to live better.

Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.


Nicox signed with Samil Pharmaceutical an exclusive license agreement for the development and commercialization of ZERVIATE® in South Korea.

Samil Pharmaceutical, with 71 years of experience in the pharmaceutical industry, is considered as one of the leading Korean companies specialized in the field of ophthalmic medicines including the research and development of drugs in the field of ophthalmology


Nicox and Kowa Company, Ltd. entered into an exclusive license agreement for the development and commercialization of NCX 470 in Japan.

Kowa is a privately held, multinational company headquartered in Nagoya, Japan.Established in 1894, Kowa is actively engaging in various business fields including the trading of textiles, machinery, and construction materials, in addition to the manufacturing and sales of medicines, medical equipment, vision units, energy saving and energy creating products.

Kowa’s pharmaceutical business is focused on research and development for three main activities in lifestyle-related diseases (dyslipidemia, type 2 diabetes, and atherosclerosis), ophthalmology and anti-inflammatory agents.

For more information, please see https://www.kowa.co.jp/eng/

Click on a partner logo to read more
All information on partnerships signed by Nicox can be found in the section Overview of the activities of the Document Universel d’Enregistrement and the subsequent press releases.